Marine-derived Streptomyces have emerged as one of the most prolific microbial resources for structurally diverse and pharmacologically significant natural products. Adaptation to highly competitive marine ecological niches, including deep-sea sediments, hydrothermal vents, mangrove ecosystems, marine invertebrates, and saline habitats, has driven the evolution of specialized biosynthetic systems capable of generating chemically complex secondary metabolites. Recent advances in genome sequencing, bioinformatics, metabolomics, synthetic biology, and artificial intelligence-assisted discovery pipelines have significantly expanded understanding of cryptic biosynthetic gene clusters (BGCs) encoded within marine actinomycete genomes. These BGCs produce structurally diverse metabolites including polyketides, non-ribosomal peptides, ribosomally synthesized and post-translationally modified peptides (RiPPs), terpenoids, alkaloids, and hybrid metabolites with potent antibacterial, antifungal, antiviral, antiparasitic, anti-inflammatory, and anticancer activities. Nevertheless, despite rapid technological progress, major translational limitations remain, including low cultivation efficiency, silent pathway expression, rediscovery of known compounds, metabolite yield instability, dereplication bottlenecks, and insufficient ecological interpretation. This critical review comprehensively discusses the biosynthetic diversity of marine Streptomyces-derived metabolites with emphasis on biosynthetic pathways, enzymatic tailoring reactions, genome mining strategies, metabolomics-guided discovery, synthetic biology approaches, and pharmaceutical applications. In addition, current limitations and future perspectives in marine natural product research are critically evaluated to highlight the transition from descriptive omics-driven exploration toward functionally validated and translationally relevant drug discovery.